Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL

NCT05658562 is registered in ClinicalTrials.gov with Tanabe Pharma Corporation as lead sponsor.

NCT NCT05658562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05658562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Open-Label Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
Lead sponsor
Tanabe Pharma Corporation
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 30, 2023
Completion date
August 31, 2028
Enrollment
46 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma